Compare ASIX & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASIX | CGEM |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 526.1M | 671.7M |
| IPO Year | N/A | 2021 |
| Metric | ASIX | CGEM |
|---|---|---|
| Price | $15.84 | $10.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $32.00 | $27.14 |
| AVG Volume (30 Days) | 478.8K | ★ 1.3M |
| Earning Date | 11-07-2025 | 11-06-2025 |
| Dividend Yield | ★ 4.00% | N/A |
| EPS Growth | ★ 35.47 | N/A |
| EPS | ★ 1.92 | N/A |
| Revenue | ★ $1,491,348,000.00 | N/A |
| Revenue This Year | $4.71 | N/A |
| Revenue Next Year | $4.59 | N/A |
| P/E Ratio | $8.34 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.10 | $5.68 |
| 52 Week High | $32.73 | $13.60 |
| Indicator | ASIX | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 45.72 | 58.77 |
| Support Level | $15.05 | $10.01 |
| Resistance Level | $16.00 | $13.33 |
| Average True Range (ATR) | 0.53 | 1.07 |
| MACD | 0.26 | -0.00 |
| Stochastic Oscillator | 89.43 | 47.06 |
AdvanSix Inc. is a diversified chemistry company playing a critical role in globally supply chains, innovating and delivering essential products for customers in a wide variety of end markets and applications that touch people's lives, such as building and construction, fertilizers, agrochemicals, plastics, solvents, packaging, paints, coatings, adhesives and electronics. The company key products includes: Nylon, Caprolactam, Plant Nutrients, and Chemical Intermediates The majority of sales is from Plant Nutrients products.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.